Therapy guide · medical education
Facial seborrheic dermatitis (facial dandruff): the full therapy pathway
The face is where seborrheic dermatitis is easiest to clear and hardest to keep clear. This is the map from the shelf antifungal to the prescription tier, and the maintenance half that decides whether any of it lasts.
Before anything else
Not everyone should start at the bottom of this pathway. These presentations are reasons to
see a clinician without waiting out an over-the-counter trial first.
- Eye pain, light sensitivity or any change in vision alongside lid-margin scaling Seek care quickly
Seborrheic disease at the lash line can extend to the conjunctiva and the cornea, and corneal involvement is the only part of this condition capable of doing permanent damage. Symptoms crossing from irritation into pain or blurring are an ophthalmic question within days, not a dermatology question in months.
- Seborrheic dermatitis that appears suddenly, spreads widely, or resists every reasonable treatment See a dermatologist soon
Abrupt, severe or unusually extensive disease in an adult is one of the recognised skin presentations of undiagnosed HIV infection, where reported prevalence reaches roughly forty per cent and climbs as immune function declines. Testing is quick, routine and does not require the eruption to look like anything in particular.
- A single patch that will not settle, bleeds, crusts, ulcerates or has a rolled or pearly edge Worth a clinician visit
Solitary lesions that behave differently from the rest of the face are not seborrheic dermatitis behaving oddly. Basal cell carcinoma, actinic keratosis and discoid lupus all sit on this list, all favour the same sun-exposed central face, and all are treated on completely different pathways.
- Facial skin that has become thin, shiny or visibly veined, or a new crop of small bumps around the mouth or nostrils after weeks of steroid use Worth a clinician visit
Topical corticosteroids on the face have a genuine ceiling, and passing it produces atrophy, telangiectasia, and the perioral or steroid-induced eruptions that follow prolonged use. These are treatment injuries rather than the condition worsening, and continuing the steroid deepens them while appearing briefly to help.
- New tremor, stiffness, slowed movement or reduced facial expression alongside longstanding seborrheic dermatitis Worth a clinician visit
Seborrheic dermatitis is substantially more common in Parkinson disease and can precede the neurological diagnosis by years. The association is real but modest, so this is a sentence for a routine appointment rather than a cause for alarm — and the skin treatment does not change either way.
Which route does this look like?
Facial seborrheic dermatitis divides by site and by what has already been tried, so a short set of questions places most people on one of three routes and on a position along it. Answers stay in this browser and are never sent anywhere.
Seven questions, none about identity and none required. The result names a route and a position, then filters the page to that column, with everything else one button away.
One thing to be clear about. This places a reader on a map; it does not say what they have. Four common conditions produce a scaling central face and two of them are treated in opposite directions, so a result here is the beginning of a conversation rather than a substitute for one.
What this looks like
No severity score for facial seborrheic dermatitis is in wide clinical use, and no staging system predicts what happens next. What follows describes two things that do change which treatments are reasonable and how long they run: how much of the face is involved, and how continuously it is present. Redness on any particular morning is a poor guide to either.
Intermittent
Weeks or months of quiet skin punctuated by episodes lasting days to a fortnight, often tracking cold weather, illness, alcohol or a stretch of poor sleep.
What it looks like: Fine, slightly greasy scale in the folds beside the nose or across the brows, on skin that is faintly pink underneath and mildly itchy or stinging.
Persistent
Something is visible in the classic sites nearly every day. Treatment clears it and stopping treatment brings it back within one to three weeks, in the same places.
What it looks like: Standing pink patches with a yellowish, waxy scale across the nasal folds, the glabella, the brows and often the outer ears, with the skin feeling simultaneously oily and tight.
Extensive, abrupt or unresponsive
Involvement well beyond the usual seborrheic sites, or an eruption that appeared suddenly and severely, or disease that has not answered a properly conducted topical course.
What it looks like: Confluent scaling across the mid-face spreading toward the cheeks, jaw, chest or back, sometimes with thickened plaques, and frequently more inflamed than greasy.
Three things that change the plan regardless of severity
Beard, moustache and hair-bearing skin
Terminal hair changes both the disease and the delivery. Sebaceous density is high, the hair traps scale and moisture, and a cream sits on the hair rather than reaching the skin beneath it. Foams, gels and lotions were designed for exactly this problem, and a beard that is never parted during application is a common reason a reasonable prescription appears to fail.
Eyelid margins involved
Scaling at the lash line is seborrheic blepharitis, and it is the one facial site where the ordinary ladder does not apply. Antifungal creams are not formulated for the eye, corticosteroids near the globe carry glaucoma and cataract risk over time, and inflammation can extend onto the surface of the eye itself. Lid hygiene is the whole first tier here, and anything past it is co-managed rather than prescribed at a distance.
Deeper skin tones
On richly pigmented skin the erythema that drives most severity judgements is difficult to see, so disease is routinely graded milder than it is. The presentation is also frequently hypopigmented rather than red, arranged in petal-like or ring-shaped patches, which is misread as a fungal infection or vitiligo often enough to matter. The pale patches are a consequence of the inflammation and usually repigment once it is controlled, though that takes months longer than the scaling does.
Immune suppression or Parkinson disease
Seborrheic dermatitis is far more common, more extensive and more stubborn in people with HIV — where prevalence rises as lymphocyte counts fall — and in Parkinson disease, where reduced facial movement and altered autonomic function appear to contribute. Neither changes which treatments are used, but both change the expected ceiling: control is achievable, and full clearance on an ordinary schedule frequently is not.
What else it could be
- Rosacea — Also central, also pink, but the scale is absent and the story is flushing, stinging and papules on the cheeks and nose rather than waxy flakes in the folds. The two coexist constantly, which is why treating one and ignoring the other stalls.
- Scalp and facial psoriasis — Sharper margins, thicker and more silvery scale, and usually evidence elsewhere — elbows, knees, nails, the gluteal cleft. Where the two are genuinely indistinguishable on the face, the overlap has its own name and is treated from both directions.
- Contact dermatitis from a product — Follows the shape of what was applied rather than the shape of the oil zones, appears one to three days after a new product, and itches more than it flakes. A face that got worse when treatment started is more often this than treatment failure.
- Tinea faciei — A true fungal infection of facial skin, typically one patch with a raised advancing edge and clearer skin in the centre, often asymmetric. It responds to antifungals in a way seborrheic dermatitis does not: it goes and stays gone.
Distinguishing these matters more here than on most pages, because two of them are made worse by the standard seborrheic routine. Where the picture is genuinely ambiguous, the therapy guides for rosacea, psoriasis and contact dermatitis each set out how their own condition is confirmed.
Why it happens
Seborrheic dermatitis is an inflammatory reaction to Malassezia yeasts, which live on virtually every adult face and feed on the fats in sebum. The reaction is the disease; the yeast is merely the trigger, and its numbers are often unremarkable. That is why the condition maps so precisely onto the oil-rich zones — the creases running from nose to mouth, the eyebrows and the skin between them, the outer ears, the beard line — and why it has nothing to do with cleanliness. Faces that are scrubbed harder get worse, reliably.
Adults with seborrheic dermatitis on the face. The scalp version has its own page: hair-bearing skin tolerates strengths, contact times and vehicles that a cheek does not, and treating the two identically is a common route to an irritated face. Infants appear here in a short dedicated section rather than on any ladder, because cradle cap behaves nothing like adult disease.
Orientation, not diagnosis. Two facts shape everything below. The condition is controlled rather than cured, so the meaningful measure is how long skin stays quiet, not whether it went away. And it is unusually easy to clear — two to four weeks of a competent antifungal settles most facial disease — which is precisely what makes the return so demoralising, because it follows something that visibly worked. This pathway therefore devotes more attention to the month after clearance than to the month before it.
No prescription needed for any of this The over-the-counter pathway
American over-the-counter regulation has an explicit category for this condition, and it is worth knowing exactly what that does and does not cover. Monograph M032 permits several actives to say the words seborrheic dermatitis on a label — zinc pyrithione, selenium sulfide, coal tar, salicylic acid and sulfur among them — with a separate, higher concentration floor for the seborrheic claim than for the dandruff claim on the same ingredient. That is a genuine first-line tier and not a consolation prize. What the shelf does not carry is the strength with the deepest evidence on facial skin specifically: ketoconazole reached American shelves through a drug approval rather than the monograph, and only at one per cent, in shampoo. The two per cent cream, gel and foam that the facial trials tested remain prescription-only.
Appropriate for: Intermittent and persistent disease confined to the usual facial sites, in someone whose skin is otherwise intact and whose eyes are uninvolved. That covers the large majority of facial seborrheic dermatitis, and a substantial share of it never needs anything further.
This chart runs in two halves that are usually treated as one. The first half clears the face and takes about a month. The second half keeps it clear and has no end, and skipping it is the single commonest reason facial seborrheic dermatitis is described as untreatable by people whose treatment worked perfectly.
The failure mode: a course that ends at the point it starts working
Almost every treatment on this page clears facial seborrheic dermatitis. Very few people are ever told what to do next, so the pack goes in a drawer when the skin looks normal, the condition returns within one to three weeks, and the sequence reads as the treatment having failed. It did not fail — it was stopped. In a trial of over three hundred people who had already cleared, continuing a weekly antifungal cut six-month relapse from roughly 47% to 19%, and in facial disease specifically, twice-weekly maintenance held remission where once-weekly did not. The lesson is uncomfortable and cheap: the schedule after clearance matters more than which product produced it.
Four things that matter more than which product ends up in the basket
- One antifungal at a time, changed only after it has been given four honest weeks. Rotating between three products in a fortnight makes the result unreadable and is the most common way a working active gets discarded.
- A corticosteroid is a sprinter, never a marathon runner. Days to a fortnight during an inflamed flare, alongside the antifungal and never instead of it, and then it stops. Facial skin kept on a steroid for months develops problems the seborrheic dermatitis was never going to cause.
- Cleansing goes down, not up. This condition looks like something that should be washed away, and every increase in surfactant, scrubbing, heat or exfoliation makes it worse. Soap substitution is a treatment step here rather than a comfort measure.
- Nothing on this chart goes near the eyes. Lid-margin scaling is a separate route with a separate first step, and antifungal washes redirected onto the eyelids are how a manageable problem becomes an ophthalmic one.
Answer as you go and the chart tracks where you are. Nothing is sent anywhere.
- Day 1You are here
Take the soap out
Stop the daily provocation before adding anything, so that whatever comes next can be judged on its own.
What this step involves
Morning
- Wash with a non-foaming, fragrance-free cleanser using fingertips, and lukewarm rather than hot water Facial seborrheic dermatitis is dry and flaky underneath the grease, and stripping surfactants worsen both halves of that at once. Substituting the wash is the one change on this chart that costs nothing and helps immediately. Browse all cleansers →
- Apply a light, fragrance-free moisturiser to the affected areas Emollients and soap substitutes are listed as first-line supportive treatment for facial disease. A lighter texture matters here more than on dry-skin conditions, since heavy occlusives on sebaceous zones are poorly tolerated. Browse all moisturizers →
- Retire scrubs, brushes, acid toners, alcohol tonics and anything applied because it stings Each of these raises permeability and inflammation on skin already producing both. Removing them is a treatment step, not preparation for one.
Evening
- Repeat the same cleanser, and nothing else new this week One change at a time is what keeps the next four weeks interpretable. A routine that changes constantly cannot be read.
Why this step: Removing the provocation first means that when the antifungal goes in, any improvement can be attributed to it rather than to whichever of five simultaneous changes happened to matter.
Ready for the next step?
Is the routine now down to a gentle cleanser, a light moisturiser and nothing that stings?
Yes, it is stripped back: Add the antifungal. Go to step 1 ↓ Go to step 1 ↓
Not yet: Stay here for a few more days. This step is short but it is not skippable — an antifungal added on top of an irritating routine is judged against a moving background.
- Weeks 1–4You are here
The clearing half — one antifungal, four weeks
Reduce the Malassezia load enough for the inflammation to settle, using a single active held steady long enough to judge.
What this step involves
Morning
- Use one antifungal wash on the affected areas, most days Ketoconazole 1% and zinc pyrithione at seborrheic-dermatitis strength are the two best-tolerated choices on facial skin. Applied as a brief-contact wash and rinsed, rather than left on, which is how the tolerance problem is managed. Browse all ketoconazole products →
- Where the same product is not suiting facial skin, zinc pyrithione at 0.95% or above is the gentler equivalent Checking the concentration is worth the ten seconds. Below that figure the product carries a dandruff claim rather than a seborrheic dermatitis one, and the difference is threefold. Browse all zinc pyrithione products →
- Follow with the same light moisturiser Antifungal washes are drying, and a face that becomes tight and flaky from treatment is easily mistaken for a face that is not responding. Browse all moisturizers →
Evening
- Where thick scale has built up along the hairline or in the brows, soften it first with a salicylic acid preparation for a few days An antifungal cannot reach skin through a plate of adherent scale. This is a short opening move that stops once the surface is clear. Browse all salicylic acid products →
Why this step: Four weeks is the trial length the clearance evidence rests on, and it is long enough that a slow responder is not mistaken for a failure.
What's normal: Mild dryness and a little tightness are ordinary and settle. Sharp stinging that persists after rinsing, spreading redness, or skin that is worse each week rather than better, is a reaction to the product rather than a slow response to it — that is a reason to stop, not to persevere.
Ready for the next step?
Has one antifungal been used consistently for four weeks without switching products?
Yes, four weeks on one active: There is now something to read. Go to step 3 ↓, or to step 2 first if the skin is inflamed rather than just flaky. Go to step 2 ↓
Not yet, or it has been switched: The clock restarts from the last change. Pick one and hold it — a rotation cannot be interpreted, and the four weeks is what makes the next reading mean anything.
- Any point in weeks 1–4, if neededYou are here
If it is inflamed rather than flaky — a short, dated steroid course
Take the heat out of an angry flare quickly, while the antifungal deals with the cause underneath it.
What this step involves
Morning
- Continue the antifungal wash unchanged The corticosteroid is added to the plan, never substituted into it. A steroid used alone relieves the appearance while leaving the driver untouched, which guarantees the relapse.
Evening
- Hydrocortisone 1% to the inflamed areas only, with a stop date chosen before the first application Days to a fortnight, on the red patches rather than the whole face. In the United Kingdom this specific use is behind a pharmacist conversation and carries a seven-day ceiling on unsupervised use, and that restriction reflects what happens to facial skin past it rather than an administrative preference.
Why this step: Speed has real value when a face is visibly inflamed, and a mild steroid delivers it. The reason this step is boxed in by a date is that the same drug used for months produces thinning, visible vessels and eruptions that outlast the condition it was treating.
What's normal: Relief within days is expected. A face that flares again each time the steroid stops is telling a clear story: the antifungal half of the plan is not doing enough, and the answer is to strengthen that half rather than to extend this one.
A steroid that has become a near-daily habit over many weeks is not stopped abruptly. That situation is worth raising with a pharmacist or prescriber, who will usually taper it while an antifungal takes over the work.
Ready for the next step?
Has the steroid stopped on or before its planned date, with the antifungal still running?
Yes, it has stopped: Good. Go to step 3 ↓ Go to step 3 ↓
It is still being used, or it keeps being restarted: That is the signal the plan needs changing rather than continuing. Recurrent steroid use on the face is one of the escalation triggers at the checkpoint below.
- Week 5 onwardYou are here
The half nobody is told about — drop the frequency, do not stop
Hold the clearance on the lowest schedule that works, applied to the sites that flare whether or not anything is visible there.
What this step involves
Morning
- Continue the same antifungal, reduced to roughly two applications a week This is the step the whole page exists for. In the trial that tested it, weekly prophylaxis after clearance cut six-month relapse from around 47% to 19%; in facial disease, twice-weekly application outperformed once-weekly at holding remission. The frequency is the treatment now. Browse all ketoconazole products →
- Apply it to the usual sites, not to whatever is currently visible Treating only what can be seen means always arriving after the flare has started. Maintenance is applied to the folds, brows and ears while they look normal, which is the point of it.
Evening
- Keep the gentle cleanser and the moisturiser permanently The supporting routine does not step down. It is the background everything else is judged against, and changing it is what makes a stable period suddenly unstable. Browse all cleansers →
Why this step: Clearance and maintenance are two different treatments with two different frequencies, and only the first one is ever printed on a box. Making the second one explicit is what converts a recurring problem into a controlled one.
Ready for the next step?
Has a reduced schedule been running for four weeks, through at least one period that would normally have brought a flare?
Yes, four weeks on maintenance: That is the checkpoint. Read the result below ↓ Go to step 4 ↓
Not yet: Keep going. A maintenance schedule judged after ten days has not been judged at all — the interval it has to survive is measured in weeks.
- OngoingYou are here
Living with it — reading a slip early
Recognise a return before it becomes a flare, and know which adjustments are within reach without an appointment.
What this step involves
Morning
- Treat the first return of fine scale in the nasal folds as the signal, not the itch Scale reappears before redness does. Stepping the frequency back up for a fortnight at that point usually prevents the whole episode, and costs a few extra applications.
- Expect the schedule to need to be denser in winter and during stressful stretches The condition tracks cold, dry weather, illness, poor sleep and alcohol. A schedule that holds in July and slips in January is behaving normally rather than failing.
Evening
- Keep one antifungal in reserve rather than replacing it whenever a flare arrives The instinct at a slip is to buy something different. The evidence points the other way: the same active at a higher frequency for two weeks is the move, and novelty is what makes the pattern unreadable again.
Why this step: This condition is held rather than cured, and the skill it asks for is pattern recognition rather than product selection. Someone who can name their own flare interval is managing it well.
Ready for the next step?
Is there a schedule that keeps the face quiet most of the time, with flares that settle when frequency goes back up?
Yes, that is roughly the picture: That is what good control looks like on this condition. Nothing further is needed unless the picture changes. Go to the checkpoint ↓
No — it keeps breaking through: Breakthrough on a properly held maintenance schedule is the point at which the prescription tier has something to add. Read the checkpoint below ↓
The eight-week reading, taken in two parts
Four weeks after starting an antifungal, and again four weeks after dropping to a reduced schedule. Counted from the first day of consistent use, not from the day the product was bought.
How to judge it: The first reading asks whether the face cleared. The second asks whether it stayed clear on less. Almost everyone passes the first, which is why taking only that reading produces such a misleading picture of how well this condition is being controlled.
Did it clear, and did the clearance survive a reduced schedule?
The plan is working as designed
This is the intended result and it is worth naming, because it does not feel like success — it feels like still using something. Continuing at this frequency indefinitely is the treatment rather than a failure to finish it, and the schedule can be tested downward later by dropping one application a week and watching for a month.
A schedule problem, not a product problem
This is the most common answer and it is the one most often misread as treatment failure. A condition that clears reliably has already demonstrated that the active works; what has not been established is the frequency that holds it. The next move is a maintenance schedule kept running through the quiet weeks rather than a different purchase, and if that has genuinely been tried at two applications a week without holding, that is the version of this answer worth taking to a clinician.
The over-the-counter tier has been tested and has not delivered
Failure to clear after a properly conducted course is a different finding from failure to hold, and it is the one that justifies escalation. Two things sit behind it in roughly equal measure: the vehicle, since nothing on an American shelf leaves an antifungal on facial skin, and the diagnosis, since rosacea, psoriasis and contact dermatitis all present here and none of them answers to an antifungal.
Stop rather than escalate
Skin that is worse on treatment than it was before is not under-treated. Contact allergy to an antifungal, irritation from an over-stripped routine, and a different diagnosis entirely all look like this, and all of them are made worse by increasing the dose. The useful next step is stopping the suspected product, holding the gentle routine for two weeks, and going in with a clear account of what was applied and when.
What does not wait for the eight weeks
Eye pain, light sensitivity or blurred vision alongside lid-margin scaling is an ophthalmic question within days. A face that erupted suddenly and severely, or disease spreading well beyond the seborrheic zones — particularly alongside weight loss, oral thrush or recurrent infections — is a reason to be assessed rather than to complete a trial. A single patch that bleeds, crusts or ulcerates is not this condition and needs looking at. And facial skin that has become thin, shiny or visibly veined, or has developed small bumps around the mouth or nostrils after weeks of steroid use, is being injured by the treatment: the checkpoint is irrelevant, and continuing is what deepens it.
Nothing on this chart requires blood tests or supervision. The only thing worth tracking is dates — when an active started, when it was reduced, and when a flare broke through — because the entire reading at the checkpoint depends on knowing how long things actually ran, and memory reliably compresses four weeks into two.
Where the over-the-counter pathway ends
It ends at the vehicle, more often than at the strength. Everything reachable without a prescription in the United States is a wash, and a wash cannot hold an antifungal against inflamed skin for hours — which is exactly what the trials behind this condition tested. That gap is the honest reason a large share of people who have done everything on this chart correctly still need a prescription, and it is a supply gap rather than a personal one. It ends secondarily at the corticosteroid ceiling: mild steroids buy days, never months, and a face that needs one most weeks needs a steroid-sparing drug instead, all of which are prescription-only.
See the prescription pathway →Facial seborrheic dermatitis (facial dandruff): the full therapy pathway · dermapproved.com/treatments/facial-seborrheic-dermatitis/ · not a diagnosis — confirm anything you act on with a clinician
What to expect
The honest headline is that facial seborrheic dermatitis is controlled rather than cured, and hearing that at the start is more useful than discovering it after the third relapse. Clearance itself is usually quick — scale goes within two to four weeks on a competent antifungal, and the pinkness fades behind it over a few weeks more. What takes longer is establishing the frequency that holds it, which needs at least a couple of months of watching. Where pale patches have been left behind on richly pigmented skin, those are the slowest part of all: pigment returns over months once the inflammation is controlled, long after the scaling has stopped. Nothing about that timeline is a sign of a treatment underperforming.
- Relapse after stopping is the expected behaviour of a controlled condition, not evidence that the treatment failed — the trial evidence for maintenance exists precisely because relapse is the norm
- A maintenance schedule is applied to the sites that flare while they look normal, which feels unnecessary and is the entire mechanism
- Winter, illness, poor sleep and alcohol all tighten the schedule that is needed, so a routine that held in summer and slips in January is behaving predictably
- Four weeks on one active beats two weeks each on two, because a rotation cannot be attributed and a working product frequently gets discarded that way
Worth going back to a clinician if a properly held maintenance schedule stops holding, if a corticosteroid has become something used most weeks, if the disease spreads beyond the face, if a single patch starts behaving differently from the rest, or if lid symptoms move from grittiness toward pain or altered vision. Also worth returning for the quieter reason: someone who has been clearing and relapsing for years on repeated short courses has never had the maintenance conversation, and that conversation changes more than another prescription would.
What would bring you back sooner
Whatever step you are on, these do not wait for the end of a trial period. They are the same
presentations listed at the top of this page — repeated here because that is where they
matter, rather than where they were easiest to put.
- Eye pain, light sensitivity or any change in vision alongside lid-margin scaling Seek care quickly
- Seborrheic dermatitis that appears suddenly, spreads widely, or resists every reasonable treatment See a dermatologist soon
- A single patch that will not settle, bleeds, crusts, ulcerates or has a rolled or pearly edge Worth a clinician visit
- Facial skin that has become thin, shiny or visibly veined, or a new crop of small bumps around the mouth or nostrils after weeks of steroid use Worth a clinician visit
- New tremor, stiffness, slowed movement or reduced facial expression alongside longstanding seborrheic dermatitis Worth a clinician visit
Prescription only — from here on, this is a clinician's decision The prescription pathway
Why this tier exists. Every over-the-counter option here is a wash. Nothing on an American shelf delivers an antifungal to facial skin in a cream that stays there, and for skin that is inflamed rather than merely flaking, a leave-on vehicle is a real advantage rather than a preference. That gap — not potency, and not evidence — is what most often ends the over-the-counter tier and starts the prescription one.
Facial seborrheic dermatitis divides by site rather than by severity, because the lash line, the beard and the folds beside the nose each rule out something the others permit. Sites run across the top; how far treatment has had to go runs down the side.
The same pathway in full below — each step names what it involves, why it sits where it does, and what tells you it's time to move up. Tap any therapy to jump to its detail.
The central-face pattern — folds, brows, glabella and ears
The ordinary presentation, and the route most people are on: greasy scale and pink skin distributed across the oil-rich centre of the face, with the eyes uninvolved.
You reach this column when: Nothing has cleared after four weeks of proper use, or clearance cannot be held on any reduced schedule, or a corticosteroid has become something used most weeks rather than occasionally.
- Prescription topical
The same idea in a vehicle that stays on the skin
Prescription-strength azole creams, gels and foamsCiclopirox olamine 1%Mild to moderate topical corticosteroidsWhy this step sits here: The step from the shelf to the clinic here is smaller than it sounds: the mechanism does not change, the vehicle does. A cream, gel or foam left on the skin reaches inflamed tissue that a wash cannot, and that alone resolves a large share of what looks like antifungal failure. The corticosteroid chip reads as high because the Cochrane synthesis of topical anti-inflammatories is substantial, and that strength describes short-term clearance only, which is the sole role it is given here.
These are alternatives within one step rather than a sequence. The choice turns on what the skin has already refused, how much inflammation is present, and whether hair is in the way.
- Prescription-strength azole cream, gel or foam backed by large randomized trials
Reached for where a rinse-off antifungal helped but did not finish the job, since it keeps the same mechanism and changes only how long it stays in contact with the skin.
- Ciclopirox olamine cream backed by smaller studies
Suits skin that has reacted badly to an azole or has stopped responding to one, because its mechanism is unrelated and cross-reaction is not expected.
- A short mild-to-moderate corticosteroid course alongside backed by large randomized trials
Added where inflammation rather than scaling is the dominant feature and speed matters, with a defined stop date set at the same appointment.
When to move up
- A fair trial
- Four weeks of regular application, then four weeks of a reduced maintenance frequency. Twelve weeks total is the point at which this rung has genuinely been tested.
- Improvement looks like
- Clearance at four weeks, and no return of scale over the following month on roughly weekly application.
- Move up if
- Clearance is not achieved, or holding it requires a corticosteroid to be running more or less continuously, which is not a schedule facial skin tolerates.
→ The next step up this pathway.
-
- Prescription topical
Steroid-sparing maintenance, held indefinitely
Topical calcineurin inhibitorsRoflumilast 0.3% foamMetronidazole 0.75% gelLithium gluconate and succinate ointmentsWhy this step sits here: This is where the pathway stops chasing clearance and starts defending it. The chips deserve a word: lithium is marked as smaller-studies despite its trial enrolling 269 people, because a single trial is a single trial regardless of size, and metronidazole rests on sixty participants. Neither chip is a judgement about whether the drug works — it describes how much has been published, which is the honest thing a phrase on a card can carry.
Every option on this rung exists for the same purpose: continuous facial anti-inflammatory control without the atrophy that ends corticosteroid use. Which one is prescribed depends heavily on country.
- Topical calcineurin inhibitor on a fixed twice-weekly schedule backed by large randomized trials
Fits where the problem is relapse rather than clearance, since this is the only option here with a randomised trial of a facial maintenance schedule behind it.
- Roflumilast foam once daily backed by large randomized trials
Fits where a different mechanism is wanted after antifungals and steroids have both been tried, and where the reader is in a country that has registered it.
- Metronidazole gel backed by smaller studies
Fits where rosacea and seborrheic dermatitis are running together on the same face, which is common enough that one prescription covering both is worth having.
- Lithium gluconate or succinate ointment backed by smaller studies
Available in a small number of European markets, and reached for there when the azoles have not held.
When to move up
- A fair trial
- Eight to twelve weeks, which is long enough for a maintenance schedule to be tested across at least one period that would normally have produced a relapse.
- Improvement looks like
- Long stretches of quiet skin punctuated by short flares that settle on the existing regimen, rather than a cycle of clearing and returning.
- Move up if
- Disease is spreading beyond the face, or every topical route has been properly tried and none holds, or the extent has become impractical to treat topically at all.
→ The next step up this pathway.
-
- Prescription oral
A systemic antifungal course
Why this step sits here:
Two oral antifungals, chosen on interactions, liver history and where on the body the disease actually sits — not on any established ranking between them.
- Itraconazole, as short pulses backed by smaller studies
Considered where facial disease is part of a wider picture and relapse prevention is the goal, since the trial behind it measured relapse rather than clearance alone.
- Terbinafine, as a defined course backed by smaller studies
Weighed where the covered sites carry most of the disease, because the trial that separated sites found its benefit there and not on exposed skin.
The ladder ends here for face-limited disease, and it ends with a caution that belongs on this page more than on any other. The one randomised trial of an oral antifungal that analysed the face separately from covered skin found no significant benefit on the face. That does not make an oral course unreasonable where disease extends well beyond it, but it does mean a tablet is not a stronger version of the cream for someone whose problem is confined to the nasal folds. Where facial disease alone has defeated every topical route, the next conversation is usually about whether the diagnosis is right rather than about a bigger drug.
-
What clearance hands over to on this route
Clearance is a checkpoint here, not a finish, and the treatment that follows it is the same treatment at a lower frequency rather than nothing at all. The evidence for that is unusually concrete. Weekly antifungal prophylaxis after clearance cut six-month relapse from around 47% to 19% in a trial of over three hundred responders, and in facial disease specifically, twice-weekly application of a calcineurin inhibitor held remission where once-weekly application did not — a dose-response for maintenance itself. The practical shape is an ongoing schedule of one to three applications a week, continued through quiet periods, and stepped briefly back up when a flare breaks through.
Lid margins — seborrheic blepharitis
Scaling, crusting or redness along the base of the lashes, with or without grittiness. The eye is close enough that almost nothing from the main route applies here.
You reach this column when: Symptoms persist after a properly conducted trial, or lashes are being lost, or the lid margin is distorted, or grittiness has become pain or light sensitivity — the last of which does not wait for the six weeks to elapse.
- Specialist care
Co-managed treatment of the lid margin
Why this step sits here:
This route is short on purpose, and its shortness is the finding rather than a gap. Everything past lid hygiene sits beside the eye, where a corticosteroid used unsupervised can raise intraocular pressure or accelerate a cataract, and where inflammation reaching the cornea is the one complication of this condition capable of doing lasting harm. So the ladder does not climb through a series of stronger creams — it hands over. In practice that means an optometrist or ophthalmologist alongside whoever is treating the facial skin, and lid hygiene continuing underneath whatever is added rather than being replaced by it.
Lid care does not have an end date
Seborrheic blepharitis behaves like the skin disease it belongs to: it settles with treatment and returns when treatment stops. The difference is that the maintenance here costs nothing and carries no drug exposure, so the reduced schedule can be held indefinitely without any of the trade-offs that constrain the facial ladder. Most people who have controlled it well are doing several minutes of lid care a few times a week, permanently, and treating a return of morning crusting as a signal to go back to daily for a fortnight.
Extensive, abrupt or treatment-resistant disease
Disease spreading well past the seborrheic zones, or arriving suddenly and severely, or refusing a topical course that was genuinely completed. This route asks a different first question from the others.
You reach this column when: The presentation was abrupt or severe, or involves large areas, or arrived alongside weight loss, oral thrush, fevers or a known immune condition — any of which makes assessment the immediate next step rather than a later one.
- Prescription topical
Prescription topical treatment across the affected area
Prescription-strength azole creams, gels and foamsMild to moderate topical corticosteroidsRoflumilast 0.3% foamWhy this step sits here: Extensive disease is still treated topically first where the surface area allows it, because the alternative is a systemic drug for a condition that is not dangerous. Vehicle choice carries more weight than usual once large areas are involved — foams and lotions spread over a chest or a back in a way creams do not — and potency is still constrained on the face even where a stronger preparation is being used elsewhere on the body.
When to move up
- A fair trial
- Four to eight weeks of treatment applied to everything that is affected rather than to the worst of it.
- Improvement looks like
- The affected area shrinking rather than merely paling, and the newest patches settling first.
- Move up if
- The area involved makes topical treatment impractical, or a properly applied course has not shifted it, or the disease keeps recurring within weeks of each course finishing.
→ The next step up this pathway.
- Prescription oral
A systemic antifungal
Why this step sits here: This is the rung where the site-specific evidence works in the reader's favour rather than against it. The trial that split its participants by location found oral terbinafine clearly effective on covered skin — scalp, hairline, sternum, between the shoulder blades — which is precisely the distribution that defines this route. Itraconazole's trial measured relapse prevention as well as clearance, which suits disease that has been recurring rather than merely persisting.
When to move up
- A fair trial
- A completed course plus several weeks afterwards, since the question here is as much about how long the effect lasts as about whether it works.
- Improvement looks like
- Widespread involvement receding to the usual seborrheic sites, at which point the main route's topical maintenance takes over.
- Move up if
- The disease returns quickly after a completed oral course, or oral antifungals are unsuitable because of liver disease or drug interactions.
→ The next step up this pathway.
- Phototherapy
Narrowband ultraviolet B
Why this step sits here: Phototherapy earns a rung here for a specific reason: it treats large areas without adding a systemic drug, which matters for anyone whose liver, medication list or pregnancy rules the tablets out. The cost is attendance — two or three clinic visits a week for six to eight weeks — and that, rather than the evidence, is what limits how often it is used.
When to move up
- A fair trial
- A full course of six to eight weeks at the prescribed frequency. Partial attendance does not test this modality.
- Improvement looks like
- Progressive clearing across the treated areas over several weeks, usually with the trunk answering before the face does.
- Move up if
- The course finishes without meaningful improvement, or relapse follows quickly enough that repeated courses would accumulate more ultraviolet exposure than is reasonable.
→ The next step up this pathway.
- Prescription oral
Low-dose oral isotretinoin
Why this step sits here:
The top of this route is the only treatment on the page that acts on the conditions the disease depends on rather than on the disease itself: shrinking sebaceous glands removes the lipid supply Malassezia lives on. That is why the benefit can persist after the course ends, and it is also why the drug is here rather than lower down. The evidence is a retrospective series rather than a randomised trial, the monitoring is substantial, and the pregnancy-prevention requirements are absolute. Reaching this rung for a condition that is uncomfortable and disfiguring but never dangerous is a genuine trade-off, and it is one made in conversation rather than by a pathway.
Coming back down from extensive disease
Success on this route is not a clear face but a return to ordinary facial disease, and the handover is the moment it becomes ordinary again. What follows a systemic course or a phototherapy course is a topical maintenance schedule applied to the sites that were affected — including the ones on the body, which are frequently forgotten once the face has settled. Where immune suppression or Parkinson disease was the underlying reason for the extent, the maintenance schedule usually needs to be denser than the standard one and is best treated as permanent rather than as a trial.
Facial seborrheic dermatitis (facial dandruff): the full therapy pathway · dermapproved.com/treatments/facial-seborrheic-dermatitis/ · not a diagnosis — confirm anything you act on with a clinician
When the rules change
Three groups the main ladders quietly assume away, each of which reaches a different answer rather than a smaller version of the same one.
Pregnant, breastfeeding, or planning to be
This is one of the conditions where pregnancy costs least. The whole first tier survives intact, the second tier largely does, and what comes off the table sits at a level most people never reach. Seborrheic dermatitis also commonly flares in pregnancy, driven by the same hormonal shift in sebum output, so the narrowing arrives at an inconvenient moment and it is worth knowing how little it actually narrows.
What can be used
- Antifungal washes — ketoconazole, zinc pyrithione and selenium sulfide are all rinse-off products with negligible systemic absorption and long-standing use in pregnancy
- Mild topical corticosteroids in short courses over the small area a face represents, among the most extensively used medicines in pregnancy
- The entire supporting routine: soap substitution, light moisturising, mineral sunscreen
- The complete lid-care route, which involves no drug exposure at all
- Prescription-strength topical azoles, which remain among the better-characterised topical options in pregnancy
- Narrowband UVB phototherapy where extent justifies it, since it adds no systemic drug
What comes off the table
- Oral itraconazole, which is contraindicated in pregnancy and requires contraception during and after treatment
- Oral terbinafine, avoided on the straightforward grounds that this condition is never urgent enough to justify systemic antifungal exposure that can wait
- Oral isotretinoin, absolutely contraindicated and prescribed only within a formal pregnancy-prevention programme
Topical calcineurin inhibitors sit in the middle rather than in either list: absorption through intact facial skin is very low and no pattern of harm has emerged, but the human data remain limited, so continuation is a case-by-case decision with the prescriber. Application around the nipple is generally paused while breastfeeding for the practical reason of ingestion rather than any established risk.
Infants — cradle cap and the napkin area
Infantile seborrheic dermatitis is a different clinical entity wearing the same name. It appears in the first weeks of life, affects the scalp and the napkin area, and resolves on its own within months. It does not itch the way adult disease does, and it is not the beginning of a lifelong condition. Almost everything on the ladders above is unnecessary here, and the management is deliberately minimal.
What can be used
- Emollients and plain oils to soften scale, left on briefly and then washed out with a gentle shampoo
- Soft brushing of loosened scale after softening, without picking at anything adherent
- Frequent nappy changes and a barrier preparation where the napkin area is involved
- Mild antifungal or low-potency anti-inflammatory preparations where a clinician judges them necessary, which is uncommon
What comes off the table
- Adult medicated shampoos, which are formulated for adult skin and adult scalps
- Keratolytics such as salicylic acid over large areas, given salicylate absorption through a large surface-area-to-weight ratio
- Removing adherent scale by force, which breaks skin and risks infection
Two things warrant a clinician rather than watchful waiting: an eruption resembling stubborn seborrheic dermatitis that does not resolve, particularly around the mouth and napkin area with poor growth, which can indicate zinc deficiency; and any infant who seems unwell, is feeding poorly, or has widespread involvement.
Reduced immune function, and Parkinson disease
Both associations are strong enough to change what a realistic outcome looks like. Reported prevalence in people living with HIV reaches around forty per cent and rises as immune function declines; the condition is also markedly more common in Parkinson disease, where reduced facial movement and autonomic change appear to contribute. Neither alters which drugs are used. Both alter the ceiling, and saying so is more useful than implying an ordinary schedule should produce an ordinary result.
What can be used
- The full topical ladder, generally at a denser maintenance frequency than the standard schedule
- Steroid-sparing options as the maintenance backbone, since the need here is continuous rather than intermittent
- Systemic antifungals where extent justifies them, with the usual interaction review
- Practical adaptations where applying a cream to one's own face is difficult, which is a real and rarely-asked-about barrier in Parkinson disease
What comes off the table
- Treating incomplete clearance as treatment failure, when a lower ceiling is the expected outcome in this group
- Prolonged facial corticosteroid use as a substitute for a maintenance drug, since the need is long-term by definition here
- Assuming an established immune diagnosis explains an abrupt change, when a sudden severe eruption may be signalling a change in immune status itself
Where seborrheic dermatitis appears abruptly and severely in an adult with no known cause, HIV testing is a routine and appropriate step. It requires no particular appearance to justify it, and it is quick.
How an appointment actually happens, what to take to it, and how to keep your skin liveable while a prescription or procedure does its work.
What seeing a dermatologist actually looks like
Most facial seborrheic dermatitis is managed in primary care or by a pharmacist, and a dermatology referral is the exception rather than the target. What earns a referral is a picture that has not answered a properly conducted topical course, disease extending well beyond the face, uncertainty about the diagnosis, or lid involvement that needs an eye assessment alongside. The appointment tends to be short, so what is brought to it does a disproportionate amount of the work.
What to bring
- A dated list of every active tried, at what strength, how often, and for how many weeks — the weeks are the part that gets compressed in memory
- A note of whether the skin ever cleared, and how long it stayed clear afterwards, which is a different question and the more useful one
- Photographs taken in daylight at the worst point, since skin is often unhelpfully quiet on the day of an appointment
- A current medication list, which decides whether an oral antifungal is even a candidate
Questions worth asking
- Once this is clear, what does the maintenance schedule look like and how long does it run?
- Is there a steroid-sparing option that could be used continuously instead of short steroid courses?
- Does this look like seborrheic dermatitis alone, or is something overlapping with it?
- Which vehicle suits the areas involved — is a foam or lotion better than a cream here?
- What would be the sign that this needs escalating rather than adjusting?
Cost and access. The over-the-counter tier is inexpensive almost everywhere, and the concentration that matters is printed on packs that cost a few pounds or dollars. Above that, cost diverges sharply by country: a prescription-strength azole cream is a pharmacy purchase in the United Kingdom and a prescription in the United States, while roflumilast foam is available only in markets that have registered it and is priced accordingly. Calcineurin inhibitors are widely available as generics and are usually the least expensive of the steroid-sparing options.
A general practitioner can diagnose this, prescribe the first two rungs, and set up a maintenance schedule, which covers the great majority of cases. Asking specifically about what happens after clearance is worth doing at that appointment, because the maintenance half is the part most likely to go unmentioned in a consultation focused on the flare in front of it.
Finding someone to see
Routes to a clinician differ by country, and for this condition the first appointment is usually with a family doctor or a pharmacist rather than a specialist.
- US Find a Dermatologist American Academy of Dermatology Searchable by location and condition, and the directory confirms board certification.
- UK Dandruff and seborrhoeic dermatitis NHS The NHS covers this condition under its dandruff page, which sets out when to see a pharmacist and when to see a GP.
- Canada Find a Dermatologist Canadian Dermatology Association Certified dermatologists by city or postal code; a referral from a family doctor is generally needed first.
Regions are listed only where a directory could be verified, which is not a statement about care available elsewhere.
Skincare alongside therapy
On most conditions the supporting routine makes the treatment tolerable. Here it is closer to being part of the treatment: emollients and soap substitutes are listed among the first-line measures for facial disease, and a stripping wash undoes an antifungal faster than the antifungal can work.
Facial seborrheic dermatitis is greasy and dry at the same time, and almost every instinct the greasy half provokes makes the dry half worse. The routine below is chosen to reduce provocation rather than to add benefit: a wash that does not strip, a moisturiser light enough for sebaceous skin, and nothing whose selling point is that it can be felt working. It stays constant underneath every rung of every route, and it does not step down when the treatment does.
The constant routine, underneath whatever else is running
This does not change between rungs. It is the same three or four actions during a flare, during maintenance, and during a prescription course, and its stability is what makes everything else readable. Changing it at the same time as changing a treatment is how a clear result becomes an ambiguous one.
Do
- Wash with a non-foaming, fragrance-free cleanser using fingertips, in lukewarm water, no more than twice a day
- Apply a light fragrance-free moisturiser while the skin is still slightly damp, including over the areas being treated
- Pat dry with a clean towel rather than rubbing, which matters more in the nasal folds than anywhere else
- Keep the routine identical for the four weeks a treatment is being judged over
Avoid
- Foaming or stripping washes, and anything that leaves the face feeling squeaky
- Scrubs, cleansing brushes and exfoliating cloths, which raise inflammation while removing less scale than a keratolytic does
- Hot water on the face, which increases both redness and the sense of tightness afterwards
What that looks like on a shelf: a gentle cleanser, a barrier moisturizer.
Sun protection where treatment has changed how skin handles light
Sunlight has an ambiguous relationship with this condition — many people improve in summer, and phototherapy exists for exactly that reason. What changes the calculation is treatment: calcineurin inhibitors raise local photosensitivity, isotretinoin makes skin more reactive generally, and skin recovering from months of scaling burns more readily than it looks like it should.
Do
- Use a mineral filter on treated facial skin, which stings less than chemical filters on inflamed or fissured areas
- Reapply on days spent outdoors rather than treating a morning application as covering the day
- Keep using it through winter where a calcineurin inhibitor is running, since the photosensitivity is not seasonal
Avoid
- Deliberate sun exposure as a treatment, which trades a modest and temporary improvement for cumulative damage
- Alcohol-heavy sunscreen sprays on skin that is already fissured beside the nose
- Assuming a moisturiser with an SPF figure delivers that figure at the amount actually applied to a face
What that looks like on a shelf: a mineral sunscreen.
Where a beard or moustache is in the way
Hair-bearing facial skin is the site where good treatments most often appear to fail, and the reason is nearly always delivery rather than drug. A cream applied over a beard sits on the hair; the skin underneath receives very little of it. Foams, gels and lotions were designed for this, and parting the hair during application does more than changing the prescription would.
Do
- Choose a foam, gel or lotion over a cream wherever hair is involved
- Part the hair and apply to the skin beneath it rather than massaging the product across the surface
- Rinse an antifungal wash thoroughly out of the beard, since residue left in hair is a common cause of ongoing irritation
- Trim shorter during a flare if that is acceptable, which makes every application meaningfully more effective
Avoid
- Beard oils and heavy balms during a flare, which add the lipids the yeast feeds on
- Aggressive shaving over inflamed skin, which converts scaling into fissuring
- Judging a treatment as ineffective on hair-bearing skin without having first checked that it reached the skin
What that looks like on a shelf: a gentle cleanser.
Around the eyes, where the facial routine stops
Everything above stops at the orbital rim. The lid margin needs warmth, gentle mechanical cleaning and lubrication, and it does not need any of the actives used on the rest of the face. This is also the part of the routine that most rewards patience, since improvement is measured across weeks rather than days.
Do
- Apply a comfortably warm compress for several minutes before cleaning, so the blocked secretions soften first
- Clean along the base of the lashes gently, with a sterile lid wipe or a preservative-free lid cleanser
- Use preservative-free artificial tears where the eyes feel dry or gritty through the day
- Continue several times a week once symptoms settle, since this is maintenance like everything else here
Avoid
- Antifungal washes and medicated shampoos redirected onto the eyelids
- Baby shampoo as a lid cleanser, a widely repeated substitute whose surfactant worsens ocular surface dryness
- Compresses hot enough to feel hot rather than warm, on skin thin enough to scald
What that looks like on a shelf: a gentle cleanser.
Skin recovering from over-treatment
A face that has been on a steroid for months, or scrubbed and acid-toned for years, needs a period where nothing is being done to it beyond repair. This is the least satisfying part of the pathway and frequently the most productive, because a great deal of what gets read as stubborn disease is accumulated irritation sitting on top of it.
Do
- Reduce to a cleanser and a moisturiser only for two weeks, with any steroid taper handled by a prescriber
- Expect the first week to look worse rather than better, which is the ordinary course and not a relapse
- Reintroduce one product at a time afterwards, leaving at least a fortnight between additions
Avoid
- Adding a soothing product to compensate, which adds another variable to skin that needs fewer
- Stopping a long-running facial steroid abruptly without advice, given the rebound that typically follows
- Treating the first two weeks of a strip-back as evidence that it is not working
What that looks like on a shelf: a gentle cleanser, a barrier moisturizer, an emollient for everywhere.
The supporting shelf
A gentle cleanser
A barrier moisturizer
A mineral sunscreen
An emollient for everywhere
The role links above lead to category listings rather than to ranked recommendations, because what grades well in a catalog changes as products are re-scored and a fixed suggestion on a medical page goes stale without anyone noticing. What does not go stale is the specification: fragrance-free, non-foaming, light enough for sebaceous skin, and short on ingredients. Two further notes worth carrying. The sunscreen role here is deliberately mineral rather than the general daily filter used on some other guides, because chemical filters sting on fissured skin beside the nose and that is where this condition lives. And there is no occlusive role on this page at all — heavy occlusion is a genuine treatment for barrier disease elsewhere, and on skin whose problem is partly sebaceous it is more likely to provoke than to help.
Every therapy named above, in full. Look things up here; it is not meant to be read end to end.
Every therapy, explained
Reference, not reading — every therapy named anywhere above, described the way a clinician would describe it. Nobody reads this section end to end; open the one you were sent here for. Which one is right for you is the appointment's job, not this page's.
Over the counter
Available without a prescription. Each one opens with what to look for on a label, which is the part that stays true regardless of which brand is on the shelf that month.
Over-the-counter Ketoconazole 1%, the over-the-counter strength
Topical azole antifungal
Generally compatible
Ketoconazole 1%, the over-the-counter strength
Topical azole antifungal
An azole antifungal that has the largest and most consistent trial record of anything used on facial seborrheic dermatitis, and which functions as the reference treatment other options are measured against.
At the shelf
Ketoconazole 1% on the active ingredients panel, in a shampoo. There is no other over-the-counter format.
The panel matters more than the front of the bottle. American shelves carry exactly one over-the-counter ketoconazole product type, a 1% shampoo licensed for dandruff; the 2% cream, gel and foam that the facial trials used are dispensed on prescription. Applied to the face it is used as a brief-contact wash rather than left on, which is how the tolerance problem is managed rather than a compromise on strength. In the United Kingdom, Ireland and much of Europe a 2% cream is sold as a pharmacy medicine, so the same reader in a different country reaches a materially stronger product without an appointment.
Watch out for: Salon and prestige versions of the same 1%, which is a fixed regulated concentration and performs identically at any price. Also anything marketed as a ketoconazole alternative on the strength of a plant extract.
Browse all ketoconazole products in our catalog →
How it works
Blocks synthesis of ergosterol, the sterol Malassezia depends on to hold its cell membrane together. Reducing the yeast population removes the trigger for the inflammatory response, which is why the redness settles alongside the scale rather than after it.
What the evidence says well established
A Cochrane review of 51 trials and 9,052 participants found topical 2% ketoconazole reduced the risk of failing to clear by about 31% against vehicle, and produced remission rates comparable to topical steroids with roughly 44% fewer adverse effects.
Typical course
A clearing phase of two to four weeks with frequent use, then a reduced schedule of roughly once or twice a week that continues indefinitely. The second phase is the one that determines the outcome.
Commonly discussed side effects
- Dryness and tightness where it is used most often
- Transient stinging on skin that is already inflamed
- Occasional contact allergy, which presents as the treated area getting worse rather than better
- Hair dryness where a shampoo formulation runs through a beard
Worth knowing
- Not for use in or near the eye; lid-margin disease is handled on a different route
- Skin that stings sharply and stays red afterwards is reacting to the product, not responding slowly to it
- The 1% shampoo is labelled for dandruff, so a facial recommendation is off-label even where it is entirely routine
Pregnancy: Systemic absorption from a rinsed-off topical azole is very low and topical ketoconazole is widely continued during pregnancy and breastfeeding. Application around the nipple is avoided while feeding for the practical reason of ingestion rather than any established fetal risk.
Why it sits where it does: It is the active with the deepest facial evidence and the mildest adverse-effect profile among the effective options, which makes it the reasonable opening move for anyone who has not yet tried a proper antifungal course.
Over-the-counter Zinc pyrithione
Monograph antifungal and antibacterial
Generally compatible
Zinc pyrithione
Monograph antifungal and antibacterial
The most broadly tolerated of the monograph actives on facial skin, and the one whose American label may name this condition directly.
At the shelf
Zinc pyrithione at 0.95% or above in a wash-off product, if the intended target is seborrheic dermatitis rather than flaking alone.
This is the concentration distinction the front label never makes. The American monograph permits a dandruff claim from 0.3% in a rinse-off product, and a seborrheic dermatitis claim only from 0.95% — the same molecule, the same format, three times the floor. A wash sitting between those two numbers is legitimately an anti-dandruff product and legitimately not a seborrheic dermatitis treatment. The uses section on the back of the pack states which claim the manufacturer actually holds, and reading it takes less time than a comparison of the marketing.
Watch out for: Leave-on creams built around zinc pyrithione at monograph leave-on strengths, which run an order of magnitude below the wash-off band and are the weakest way to buy this ingredient.
Browse all zinc pyrithione products in our catalog →
How it works
Disrupts fungal membrane transport and copper handling, suppressing Malassezia growth. It also has activity against the skin bacteria that colonise scaling skin, which may account for part of the effect where crusting has developed.
What the evidence says strong
In a four-week randomised comparison of 331 people with dandruff or seborrheic dermatitis, zinc pyrithione reduced severity by 61% against 73% for ketoconazole — a real difference, on a product available without any consultation at all.
- A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis
Typical course
Daily or near-daily during a flare for two to four weeks, dropping to two or three times a week once the skin is quiet, held there without an end date.
Commonly discussed side effects
- Mild dryness, generally less than the other monograph actives cause
- Occasional stinging on broken or fissured skin in the nasal folds
- Rare contact allergy
Worth knowing
- Concentration decides whether this is a treatment; below 0.95% in a wash-off product it is not one for this condition
- Not for use near the eye
- Zinc pyrithione has been withdrawn from cosmetic use in the European Union, so European readers will find it in fewer products than American ones
Pregnancy: A rinse-off monograph active with negligible systemic absorption and long-standing use across pregnancy. No pregnancy-specific restriction attaches to it in the American monograph.
Why it sits where it does: Comparable enough to ketoconazole for everyday use, better tolerated than selenium sulfide, and carrying an explicit regulatory indication for this exact condition — which makes it the sensible option for skin that has already reacted to something harsher.
Over-the-counter Selenium sulfide 1%
Monograph antifungal and antiproliferative
Generally compatible
Selenium sulfide 1%
Monograph antifungal and antiproliferative
A monograph active with genuine efficacy against Malassezia, positioned here by tolerability rather than by potency.
At the shelf
Selenium sulfide 1% in a wash-off product. The 2.5% version is a prescription strength and is not on the same shelf.
Effective and monograph-recognised for this condition, and simultaneously the least pleasant option on facial skin. Stinging, dryness and a sulphurous smell that survives rinsing are the ordinary experience rather than the unlucky one, which is why it earns its keep along the hairline, in the beard and behind the ears rather than across the cheeks and nasal folds. It can lift the colour from dyed or chemically treated hair, and it discolours silver jewellery.
Watch out for: Premium formulations of a fixed regulated concentration. What differs between them is fragrance and conditioning, neither of which changes the active.
Browse all selenium sulfide products in our catalog →
How it works
Reduces Malassezia numbers and slows the turnover of skin cells in the treated area, which lowers scale production directly as well as through the antifungal effect.
What the evidence says strong
In a 236-participant randomised trial both selenium sulfide and ketoconazole outperformed placebo on scaling and itch, with ketoconazole the stronger of the two.
- A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff
Typical course
Twice weekly for two weeks, then weekly for a further two, then intermittently as required. It is not an active that suits daily facial use.
Commonly discussed side effects
- Stinging and burning, particularly in the nasal folds
- Pronounced dryness with repeated use
- A metallic or sulphurous odour that lingers after rinsing
- Lightening of dyed or bleached hair in a treated beard
Worth knowing
- Poorly suited to the central cheeks and to anyone with reactive skin
- Not for use near the eye, and it stings severely if it reaches one
- Not for use on broken or weeping skin
Pregnancy: Absorption from intact skin during brief contact is minimal and topical selenium sulfide is used across pregnancy. Application to broken skin is avoided, which is ordinary advice for this ingredient regardless of pregnancy.
Why it sits where it does: It belongs on the pathway because it works and because the monograph names the condition, and it sits below the other two because on facial skin the tolerability gap is wide enough to decide the outcome.
Over-the-counter Salicylic acid 1.8–3%
Monograph keratolytic
Generally compatible
Salicylic acid 1.8–3%
Monograph keratolytic
A keratolytic that dissolves the bonds holding scale to the skin surface, used to clear the way for something else rather than as a therapy in its own right.
At the shelf
Salicylic acid between 1.8% and 3%, which is the band the monograph permits for this claim. Cosmetic exfoliating toners sit below it and are a different product doing a different job.
This is a scale-removal step, not a treatment for the underlying process, and it is worth buying only when there is scale thick enough to matter — crusting along the hairline, waxy build-up in the brows, plates in a beard. Softening that first is what lets an antifungal reach skin instead of resting on a layer of dead cells. Once the surface is clear it has no further role, and continuing it simply dries the face.
Watch out for: Facial scrubs and exfoliating brushes bought for the same purpose. Mechanical abrasion on inflamed seborrheic skin reliably makes the redness worse while removing less scale than a keratolytic does.
Browse all salicylic acid products in our catalog →
How it works
Breaks down the intercellular cement between corneocytes, loosening adherent scale so it can be washed away. It has no meaningful antifungal or anti-inflammatory action at these concentrations.
What the evidence says promising
Recognised in the American monograph for the control of seborrheic dermatitis at 1.8 to 3%, and long used in clinical practice for descaling before antifungal treatment. The evidence supports its descaling role more firmly than any independent effect on the disease.
Typical course
A few days to two weeks while visible scale is being cleared, then stopped. It is an opening move rather than a maintenance one.
Commonly discussed side effects
- Dryness and tightness, often marked on facial skin
- Stinging where skin is fissured
- Redness that can be mistaken for the condition worsening
Worth knowing
- Not for use near the eye or on broken skin
- Continued past the point where scale has cleared it dries the face for no benefit
- Applying it over large areas of skin in young children is avoided because of salicylate absorption
Pregnancy: Topical salicylic acid over a limited facial area, particularly in a rinse-off product, is regarded as compatible with pregnancy. The caution attaches to extensive application over large body areas rather than to facial use.
Why it sits where it does: It is on the pathway for a narrow and real purpose: when thick scale is blocking the treatment, no amount of antifungal fixes that, and this does.
Over-the-counter Hydrocortisone 1%
Mild topical corticosteroid
Generally compatible
Hydrocortisone 1%
Mild topical corticosteroid
The mildest topical corticosteroid, used in short bursts to take the heat out of an inflamed flare while an antifungal deals with the cause.
At the shelf
Hydrocortisone 1% in a cream or ointment, and the pharmacy counter rather than the aisle in several countries.
Availability differs by country in a way that reflects a genuine clinical caution rather than an administrative quirk. In the United States hydrocortisone 1% is a general over-the-counter product. In the United Kingdom the equivalent pack carries an explicit instruction not to use it on the face without first speaking to a pharmacist or doctor, and a seven-day ceiling on unsupervised use. The face is thinner-skinned than anywhere this drug is usually applied, and the ceiling exists because of what happens past it.
Watch out for: Combination anti-itch products pairing hydrocortisone with an anaesthetic or an antihistamine, which add sensitising ingredients to facial skin without adding benefit here.
How it works
Suppresses the local inflammatory cascade — vasodilation, cytokine release and cellular recruitment — which relieves redness, itch and burning quickly. It does nothing to the Malassezia population, so the trigger is untouched.
What the evidence says well established
In a 72-participant double-blind comparison, hydrocortisone 1% and ketoconazole 2% produced improvement in 94.4% and 80.5% respectively over four weeks, with no significant difference in how quickly the condition relapsed afterwards.
Typical course
Short bursts of a few days to two weeks during an inflamed flare, alongside an antifungal, and then stopped. It is not a maintenance drug on the face and does not become one.
Commonly discussed side effects
- Thinning of facial skin with repeated or prolonged use
- Visible small vessels across the cheeks and around the nose
- Perioral and steroid-induced eruptions, which appear weeks in and worsen when the steroid is continued
- Rebound flaring on stopping after a long unbroken course
Worth knowing
- It relieves the symptom without touching the cause, so used alone it guarantees relapse
- Not for use near the eye
- Facial use is restricted to pharmacy or prescriber advice in the United Kingdom and several other markets
- A face that has been on a steroid for many weeks needs a plan for coming off it rather than an abrupt stop
Pregnancy: Mild topical corticosteroids over small areas are among the most extensively used medicines in pregnancy, and short facial courses are routinely continued. Potency and treated area are what carry the caution, and both are small here.
Why it sits where it does: The relief is genuine and fast, and the ceiling is genuine and low. It sits inside the over-the-counter tier as an accelerator on an inflamed flare and nowhere else.
Over-the-counter Lid-margin hygiene
Mechanical and thermal lid care
Generally compatible
Lid-margin hygiene
Mechanical and thermal lid care
Warm compresses and lid cleaning, which together form the first-line treatment for seborrheic blepharitis and the only part of it that requires nobody's permission.
At the shelf
Sterile lid wipes or a preservative-free lid cleanser, a reusable warmable eye mask, and preservative-free artificial tears.
This is the entire over-the-counter tier for lid-margin disease, and unlike most of this page it is a technique rather than an active. Warmth softens the material blocking the oil glands along the lash line, and gentle cleaning along the base of the lashes removes the crust and the debris that feed the inflammation. It is unglamorous, it takes weeks, and it is more effective than anything else available without an appointment. Baby shampoo is a widely repeated home substitute and a poor one, since surfactant on the ocular surface worsens dryness.
Watch out for: Antifungal creams and medicated shampoos redirected toward the eyelids, which are not formulated for the eye. Also heated devices priced far above a fabric mask that does the identical job.
How it works
Heat liquefies stagnant meibomian secretions so the glands can empty; cleaning removes accumulated scale, bacteria and lipid debris from the lash base, reducing the inflammatory load on the lid margin and the tear film.
What the evidence says promising
Lid hygiene is the consistent first step in ophthalmic practice for blepharitis of this type. The published trials are small and heterogeneous, and the recommendation rests more on clinical consistency and low risk than on large randomised evidence.
Typical course
Daily during a symptomatic period, easing to several times a week and continuing long term. Improvement is usually gradual across four to eight weeks rather than immediate.
Commonly discussed side effects
- Transient blurring after a warm compress
- Mechanical irritation if cleaning is done vigorously rather than gently
- Worsening dryness where a foaming cleanser reaches the ocular surface
Worth knowing
- Symptoms crossing into pain, light sensitivity or altered vision are no longer a lid-hygiene problem
- Compresses that feel hot rather than comfortably warm can scald thin eyelid skin
- Contact lens wearers with persistent lid inflammation are generally advised to be assessed rather than to self-manage
Pregnancy: Warmth and mechanical cleaning involve no drug exposure at all, so pregnancy and breastfeeding change nothing about this tier. That matters here, because it is one of the few routes on this page that narrows for nobody.
Why it sits where it does: It is the whole first rung of the eyelid route, because everything more potent sits near the eye and therefore sits with a clinician.
Browse the whole catalog for this condition:
What changed recently: Two developments have moved this ground since 2023, in opposite directions. In December of that year the American regulator approved roflumilast 0.3% foam for seborrheic dermatitis from the age of nine — the first genuinely new mechanism for this condition in around two decades, a phosphodiesterase-4 inhibitor rather than an antifungal or a steroid. In April 2026 a European expert panel published the first structured consensus on managing the condition, and deliberately excluded roflumilast from its recommendations, on the stated grounds that the majority of its members declined to include regimens not registered in the European Union. Neither position is a judgement on the trial data; the divergence is regulatory geography, and it is the reason advice on this drug differs so sharply depending on which country the reader is sitting in.
Prescriptions and procedures
About the brand names below. Brand names are what the pharmacy label says; the generic name underneath is what actually matters, and it is the part that stays true when a brand is discontinued or a region carries a different one. Where a region is missing from a card below, that reflects what could be verified rather than proof of absence.
Prescription labels below link to national medicines sources rather than to manufacturers, because a label describes what a regulator approved rather than what a marketing department wrote. Availability and licensed indication differ by country, and this condition has an unusually wide spread on both.
Prescription topical Prescription-strength azole creams, gels and foams
Topical azole antifungal, leave-on vehicle
Generally compatible
Prescription-strength azole creams, gels and foams
Topical azole antifungal, leave-on vehicle
The same class as the shelf antifungal at double the concentration and, more importantly, in a vehicle designed to stay on facial skin rather than be rinsed away. This is the treatment the facial trials actually tested.
What it's called at the pharmacy
Generic name Prescription-strength azole creams, gels and foams
Sold as
- Ketoconazole 2% cream and gel, and ketoconazole 2% foam — prescription in all facial formats
- Ketoconazole 2% cream is available as a pharmacy medicine as well as on prescription
Which side of the counter this sits on is the single largest international difference on this page, and it changes what a first line looks like.
Read the label
- Ketoconazole cream — prescribing information DailyMed, National Library of Medicine
How it works
Identical ergosterol blockade to the over-the-counter strength, delivered continuously instead of during a brief wash. Sustained contact is what allows the drug to act on the inflamed skin between the scale rather than only on the surface.
What the evidence says well established
The Cochrane synthesis of 51 trials rests principally on the 2% strength. A separate randomised comparison found ciclopirox olamine and ketoconazole equivalent in mild to moderate facial disease, placing them on the same rung rather than in sequence.
Typical course
A clearing phase of two to four weeks of regular application, followed by a reduced maintenance frequency of roughly once weekly that continues without a planned end.
Commonly discussed side effects
- Local burning or stinging in the first days
- Dryness and mild scaling from the vehicle rather than the drug
- Contact allergy, uncommon but presenting as steady worsening on treatment
- Foam vehicles contain alcohol and sting more on fissured skin
Worth knowing
- Not for ophthalmic use
- Steady deterioration on a correctly used azole raises contact allergy or a different diagnosis rather than resistance
- Foam and gel vehicles suit hair-bearing skin; creams suit dry cheeks
Pregnancy: Topical azoles are among the better-characterised medicines in pregnancy and systemic absorption through facial skin is low. Oral azoles are a different question entirely and are not interchangeable with this.
Why it sits where it does: It is the first prescription step because it changes the vehicle rather than the strategy — the same mechanism that was already working part-way, delivered properly.
Prescription topical Ciclopirox olamine 1%
Hydroxypyridone antifungal
Individualized — ask a clinician
Ciclopirox olamine 1%
Hydroxypyridone antifungal
A non-azole antifungal with a distinct mechanism, used where an azole has failed, has caused a reaction, or is not tolerated.
What it's called at the pharmacy
Generic name Ciclopirox olamine 1%
Sold as
- Ciclopirox 1% shampoo — prescription, labelled for seborrheic dermatitis of the scalp
- Mycoster — ciclopirox olamine 1% cream
Cream and shampoo formats are licensed differently by country, and the facial cream is not marketed everywhere the shampoo is.
Read the label
- Ciclopirox shampoo 1% — prescribing information DailyMed, National Library of Medicine
How it works
Chelates the trivalent metal cations that fungal enzymes depend on, shutting down energy production and cellular transport. Because it does not act on ergosterol synthesis, azole tolerance or allergy does not carry across to it.
What the evidence says strong
In a placebo-controlled trial of 129 people with facial disease, 63% treated with ciclopirox olamine 1% cream cleared their test lesions at eight weeks against 34% on placebo. A separate trial found it equivalent to ketoconazole on the face.
Typical course
Twice-daily application for around four weeks, stepping down to once daily for a further four, then to an intermittent maintenance frequency.
Commonly discussed side effects
- Burning or stinging at the application site
- Local dryness
- Contact sensitisation, infrequent
Worth knowing
- Not for ophthalmic use
- The shampoo format is licensed for the scalp; facial use of a cream format is what applies here
- Cross-reaction with azoles is not expected, which is the point of reaching for it
Pregnancy: Human pregnancy data for topical ciclopirox are more limited than for the azoles, and systemic absorption is low. Whether to use it during pregnancy is a decision for the prescriber, generally after the better-characterised options have been considered.
Why it sits where it does: It sits alongside the azoles rather than above them. The reason to choose it is a different mechanism for skin that has already refused one, not greater strength.
Prescription topical Mild to moderate topical corticosteroids
Topical corticosteroid, facial potency range
Generally compatible
Mild to moderate topical corticosteroids
Topical corticosteroid, facial potency range
A short prescribed course to break an inflamed flare quickly, at a potency chosen for facial skin and with a defined stopping point built in from the start.
What it's called at the pharmacy
Generic name Mild to moderate topical corticosteroids
Sold as
- Desonide 0.05% cream, lotion and gel; hydrocortisone 2.5% cream
- Hydrocortisone 1% cream on prescription for facial use; clobetasone butyrate 0.05% where a step up is judged necessary
Potency classification systems differ between countries, so a product described as mild in one market is not necessarily in the same class in another.
Read the label
How it works
Broad suppression of the local inflammatory response. It acts on the visible consequence of the condition rather than on its driver, which is why it is paired with an antifungal rather than used in place of one.
What the evidence says well established
European expert consensus places mild to moderate potency topical corticosteroids as a first-line option for short-term control of facial disease, and specifies that only mild to moderate potencies be used in order to limit the risk of skin atrophy.
Typical course
Days to a small number of weeks, running alongside an antifungal, with the antifungal continuing after the steroid stops. Prescriptions here are deliberately written short.
Commonly discussed side effects
- Skin thinning, which on the face becomes visible sooner than elsewhere
- Telangiectasia across the cheeks and around the nostrils
- Perioral dermatitis and steroid-induced rosacea after prolonged use
- Flare on withdrawal after an unbroken course
Worth knowing
- Potency and duration are what carry the risk on facial skin, and both are constrained here
- Use around the eyes raises glaucoma and cataract risk over time and is a matter for the prescriber
- A steroid alone does not alter the relapse interval, which is why it is never the maintenance drug
Pregnancy: Mild and moderate topical corticosteroids applied to a small area are extensively used in pregnancy without evidence of harm. The signal in the literature attaches to potent steroids used over large body areas, which is not this.
Why it sits where it does: Fast relief with a hard ceiling. It belongs on the rung as a partner to the antifungal, and it is the item on this page most often used for far longer than it should be.
Prescription topical Topical calcineurin inhibitors
Steroid-sparing topical immunomodulator
Individualized — ask a clinician
Topical calcineurin inhibitors
Steroid-sparing topical immunomodulator
Tacrolimus ointment and pimecrolimus cream: anti-inflammatory drugs that are not corticosteroids and therefore do not thin skin, which makes them usable on the face over long periods where a steroid cannot be.
What it's called at the pharmacy
Generic name Topical calcineurin inhibitors
Sold as
- Protopic — tacrolimus ointment; Elidel — pimecrolimus 1% cream
- Protopic and Elidel are both authorised, with facial seborrheic dermatitis an off-licence use in each case
Both drugs are licensed for atopic dermatitis rather than for this condition, so their use here is off-label in every market despite being routine.
Read the label
- Pimecrolimus cream — prescribing information DailyMed, National Library of Medicine
How it works
Blocks calcineurin in T cells, preventing the transcription of inflammatory cytokines. The effect is comparable to a topical steroid without the collagen suppression that produces atrophy, which is what makes indefinite facial use possible.
What the evidence says strong
In 75 people whose facial disease had been stabilised, twice-weekly tacrolimus 0.1% held remission across ten weeks where vehicle did not, and did so better than once-weekly application. A separate comparison found pimecrolimus and ketoconazole equivalent, at roughly 86% improvement each.
- Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial
- An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis
Typical course
A stabilising phase of a fortnight or so, then a fixed twice-weekly schedule applied to the sites that flare whether or not anything is visible there. That second phase is the treatment, not the aftercare.
Commonly discussed side effects
- Burning and stinging in the first week, which is common, expected and settles
- Flushing after alcohol in a minority of people
- Temporary increase in local sensitivity to sunlight
- Localised viral skin infections, uncommon
Worth knowing
- The early burning is the main reason courses are abandoned before they can work, and it is worth knowing about in advance
- Both carry a boxed warning regarding a theoretical malignancy risk; long-term cohort follow-up has not borne this out, and prescribing practice is to use the shortest effective intermittent schedule
- Not applied to skin that is actively infected
Pregnancy: Systemic absorption through intact facial skin is very low and no consistent pattern of harm has emerged, but human pregnancy data remain limited. Continuation is judged case by case, and the treated area being small weighs in favour of it.
Why it sits where it does: This is the drug the maintenance argument was built on. It is the only option on the page with a randomised trial of a facial maintenance schedule, and the trial answered the question this whole pathway asks.
Prescription topical Roflumilast 0.3% foam
Topical phosphodiesterase-4 inhibitor
Individualized — ask a clinician
Roflumilast 0.3% foam
Topical phosphodiesterase-4 inhibitor
The first genuinely new mechanism licensed for this condition in around two decades: a once-daily steroid-free foam that suppresses inflammation without acting on the yeast at all.
What it's called at the pharmacy
Generic name Roflumilast 0.3% foam
Sold as
- Zoryve — roflumilast topical foam 0.3%, approved December 2023 for seborrheic dermatitis from the age of nine
Only one region appears here because only one has registered it for this indication. Its absence elsewhere reflects registration status rather than any doubt about the trial result.
Read the label
- Roflumilast foam — prescribing information DailyMed, National Library of Medicine
How it works
Inhibits phosphodiesterase-4, raising intracellular cyclic AMP and damping the production of inflammatory mediators. The route is entirely different from both antifungals and corticosteroids, so failing either does not predict failing this.
What the evidence says strong
In a phase 3 trial of 457 people, 79.5% on once-daily roflumilast foam reached clear or almost clear at eight weeks against 58.0% on vehicle, with separation already visible at week two and good tolerability.
Typical course
Once daily. The pivotal trial ran eight weeks, and what an optimal long-term schedule looks like has not been established in the way it has for the calcineurin inhibitors.
Commonly discussed side effects
- Nausea, reported in a small minority
- Headache
- Application-site pain or irritation, uncommon in the trial
- Diarrhoea, infrequent
Worth knowing
- Not used in severe hepatic impairment
- A foam vehicle suits hair-bearing skin and the scalp margin as readily as bare skin
- Cost and insurance coverage are the practical constraint on this drug far more often than tolerability is
Pregnancy: Topical roflumilast is measurably absorbed, and human pregnancy data are limited given how recently it arrived. Use during pregnancy is a prescriber decision, and the better-characterised topicals are generally considered first.
Why it sits where it does: It sits on the steroid-sparing rung because that is the clinical problem it solves: sustained facial anti-inflammatory control with no atrophy risk. Geography, not evidence, is what decides whether it is reachable.
Prescription topical Metronidazole 0.75% gel
Topical nitroimidazole
Individualized — ask a clinician
Metronidazole 0.75% gel
Topical nitroimidazole
A topical better known for rosacea, with a modest but real record in facial seborrheic dermatitis, useful mainly where the two conditions are running together.
What it's called at the pharmacy
Generic name Metronidazole 0.75% gel
Sold as
- Metronidazole 0.75% topical gel, cream and lotion — licensed for rosacea
- Rozex — metronidazole 0.75% gel and cream
Licensed for rosacea in both markets; use in seborrheic dermatitis is off-label everywhere.
How it works
Not fully settled. The antibacterial action is unlikely to explain the effect at this concentration, and the working assumption is a direct anti-inflammatory and antioxidant action on the skin.
What the evidence says promising
A double-blind trial in 60 people with facial disease found around 80% improvement with metronidazole 0.75% gel and with ketoconazole 2% cream, with no statistically significant difference between them. One trial of that size supports a place on the page, not a place near the front of it.
Typical course
Applied for around four weeks to judge whether it is contributing, and continued only if it clearly is.
Commonly discussed side effects
- Local dryness and mild stinging
- Transient worsening of redness in the first fortnight
- Contact irritation from the gel base
Worth knowing
- Not for ophthalmic use
- The evidence base is a single moderate trial, and it is positioned accordingly
- Its clearest use is where rosacea and seborrheic dermatitis genuinely coexist, which they often do
Pregnancy: Systemic absorption from topical metronidazole is very low. Practice varies on whether to continue it in the first trimester, and that judgement sits with the prescriber alongside antenatal care.
Why it sits where it does: It is a reasonable option on a rung of alternatives, chosen for overlap with rosacea rather than for any advantage against seborrheic dermatitis alone.
Prescription topical Lithium gluconate and succinate ointments
Topical lithium salt
Individualized — ask a clinician
Lithium gluconate and succinate ointments
Topical lithium salt
A treatment with a good randomised result and almost no reach outside continental Europe, which is why many readers will never be offered it.
What it's called at the pharmacy
Generic name Lithium gluconate and succinate ointments
Sold as
- Lithioderm — lithium gluconate 8% gel
Availability is genuinely narrow. Only regions where marketing could be verified are listed, and there is no equivalent product on the American market.
How it works
Not established. Both an anti-inflammatory effect and a direct action on Malassezia have been proposed, and the trial evidence outruns the mechanistic account.
What the evidence says strong
A multicentre randomised study in 269 people with moderate to severe disease reported complete response in 52.0% on lithium gluconate 8% against 30.1% on ketoconazole 2%. A single trial, but a large and well-conducted one.
Typical course
Twice-daily application over about eight weeks in the trial that established it.
Commonly discussed side effects
- Local irritation and burning
- Dryness at the application site
- Greasiness from the ointment vehicle
Worth knowing
- Topical lithium salts do not produce the systemic effects associated with oral lithium and require no blood monitoring
- Not for ophthalmic use
- Availability outside a handful of European markets is the practical limitation
Pregnancy: Pregnancy data specific to topical lithium salts are sparse. Given that better-characterised options exist for facial use, the decision to use it in pregnancy rests with the prescriber.
Why it sits where it does: It shares a rung with the other steroid-sparing options because the evidence supports it, and it carries an honest caveat that the evidence is one trial and the supply is one region.
Prescription topical Prescribed treatment for the lid margin
Ophthalmic anti-inflammatory and antibiotic therapy
Individualized — ask a clinician
Prescribed treatment for the lid margin
Ophthalmic anti-inflammatory and antibiotic therapy
What is added when lid hygiene has been done properly for weeks and the lid margin is still inflamed. It is prescribed and supervised because of where it goes rather than because of what it is.
What it's called at the pharmacy
Generic name Prescribed treatment for the lid margin
Sold as
- Topical and oral tetracycline-class agents, and short courses of ophthalmic corticosteroid, are the usual components; product choice varies widely by prescriber
Specific products are omitted here deliberately. Selection for the ocular surface is an examination-dependent decision, and a list would read as a menu when it is not one.
How it works
Combines direct suppression of lid-margin inflammation with modification of the meibomian secretions themselves, which is where the tetracycline-class agents act at doses well below their antibacterial ones.
What the evidence says promising
The evidence base for blepharitis treatment is acknowledged in ophthalmic literature to be thinner than its clinical importance warrants, with small trials and inconsistent outcome measures. Practice is consistent even where the trial support is modest.
Typical course
Weeks to months, with lid hygiene continuing underneath it throughout rather than being replaced by it.
Commonly discussed side effects
- Raised intraocular pressure with prolonged ophthalmic corticosteroid use
- Cataract formation with long unsupervised steroid courses
- Photosensitivity and gastrointestinal upset with oral tetracycline-class agents
- Local stinging on instillation
Worth knowing
- Ophthalmic corticosteroids are never continued unsupervised, and pressure checks are the reason
- Corneal involvement changes the urgency entirely and is assessed rather than treated remotely
- Tetracycline-class drugs are avoided in pregnancy and in young children
Pregnancy: The tetracycline-class component is avoided in pregnancy, which narrows this route materially. Lid hygiene, warm compresses and preservative-free tears are unaffected and carry more of the load as a result.
Why it sits where it does: It is the top of the eyelid route because the eye is the one facial site where the risk of getting it wrong is permanent, and that puts every step past hygiene in front of a clinician.
Prescription oral Oral itraconazole
Systemic triazole antifungal
Avoid in pregnancy
Oral itraconazole
Systemic triazole antifungal
A short oral antifungal course used in extensive or repeatedly relapsing disease that topical treatment has not held, generally as pulses rather than as continuous therapy.
What it's called at the pharmacy
Generic name Oral itraconazole
Sold as
- Sporanox and generic itraconazole capsules — licensed for other fungal indications, not for seborrheic dermatitis
Use in seborrheic dermatitis is off-label in every market that licenses the drug.
Read the label
- Itraconazole MedlinePlus, National Library of Medicine
How it works
The same ergosterol blockade as the topical azoles, reaching Malassezia throughout the skin at once. It also concentrates in sebum, which is a plausible reason it suits a condition that lives in sebaceous zones.
What the evidence says promising
A placebo-controlled trial in 68 people with moderate to severe disease used a short initial course followed by two days at the start of each month for three months, and reported greater clinical improvement and significantly lower relapse rates than placebo.
Typical course
A short initial course followed by brief monthly pulses over a few months. Continuous long-term dosing is not how this drug is used here.
Commonly discussed side effects
- Nausea and abdominal discomfort
- Headache
- Raised liver enzymes
- Rash
Worth knowing
- Itraconazole interacts with a long list of common medicines through CYP3A4, and a full medication review precedes it
- It carries a warning regarding negative inotropic effects and is avoided in heart failure
- Liver function is considered before and sometimes during treatment
- Absorption depends on stomach acidity, so acid-suppressing drugs matter
Pregnancy: Oral itraconazole is contraindicated in pregnancy for onychomycosis and is otherwise avoided, with effective contraception advised during treatment and for a period afterwards. This is the clearest contraindication on the page.
Why it sits where it does: It sits above the topicals because it is systemic, and it sits on a rung of two because the choice between oral antifungals here turns on fit and interactions rather than on any established order.
Prescription oral Oral terbinafine
Systemic allylamine antifungal
Avoid in pregnancy
Oral terbinafine
Systemic allylamine antifungal
An oral antifungal with a genuine result in widespread seborrheic dermatitis and a specific, well-documented failure to help the face.
What it's called at the pharmacy
Generic name Oral terbinafine
Sold as
- Lamisil and generic terbinafine tablets — licensed for onychomycosis and tinea, not for this condition
- Terbinafine tablets, prescription only
Off-label for seborrheic dermatitis in both markets.
Read the label
- Terbinafine MedlinePlus, National Library of Medicine
How it works
Inhibits squalene epoxidase, a different point in the same ergosterol pathway the azoles interrupt. It concentrates in sebum and the stratum corneum, and its distribution is one proposed explanation for the site-dependent result below.
What the evidence says promising
The one trial that separated sites is the important one. Among 174 people with disease across at least three areas, six weeks of oral terbinafine beat placebo at covered sites — 70% against 45.4% — and produced no significant difference at exposed sites, which were mainly the face.
Typical course
A defined course of several weeks rather than open-ended treatment, generally where disease extends well beyond the face.
Commonly discussed side effects
- Taste disturbance, which can be prolonged and occasionally permanent
- Gastrointestinal upset
- Raised liver enzymes, with rare serious hepatic injury
- Rash, including rare severe cutaneous reactions
Worth knowing
- Liver function is checked before treatment and the drug is avoided in active liver disease
- The evidence specifically does not support it for face-limited disease, which is the whole point of this page
- Loss of taste is the adverse effect people find hardest to live with
Pregnancy: Oral terbinafine is generally avoided in pregnancy because this condition is never urgent enough to justify systemic antifungal exposure, and deferring until afterwards costs nothing clinically.
Why it sits where it does: It is on the pathway because widespread disease is part of what brings people here, and it carries an unusually explicit limit: the trial that looked at the face separately did not find a benefit there.
Prescription oral Low-dose oral isotretinoin
Systemic retinoid
Avoid in pregnancy
Low-dose oral isotretinoin
Systemic retinoid
A sebum-suppressing drug used at doses well below those familiar from acne treatment, reserved for extensive or genuinely refractory disease after topical and antifungal routes have been exhausted.
What it's called at the pharmacy
Generic name Low-dose oral isotretinoin
Sold as
- Accutane, Absorica and generic isotretinoin — licensed for severe acne, not for this condition
- Roaccutane and generic isotretinoin, prescribed under specialist supervision
Off-label here, and prescribed within pregnancy-prevention frameworks that exist because of the drug's teratogenicity.
Read the label
- Isotretinoin MedlinePlus, National Library of Medicine
How it works
Shrinks sebaceous glands and cuts sebum output substantially. Removing the lipid supply that Malassezia depends on attacks the condition further upstream than any antifungal does, which is why the effect can outlast the course.
What the evidence says limited
A retrospective study of 48 people with moderate to severe disease found symptom scores fell on low-dose regimens, with no significant difference between the two dose levels compared. European consensus lists it as a potentially effective option where topical treatment has failed.
- Efficacy and safety of oral isotretinoin in the treatment of moderate to severe seborrheic dermatitis: a retrospective study
Typical course
Low daily doses over a few months, with the intention of reaching a durable reduction in sebum rather than of clearing a flare.
Commonly discussed side effects
- Dryness of lips, eyes, nose and skin, which is universal rather than occasional
- Raised triglycerides and liver enzymes
- Muscle and joint aches
- Mood changes, which are monitored throughout treatment
Worth knowing
- Prescribed within a formal pregnancy-prevention programme with mandatory testing and contraception requirements
- Blood tests are taken before and during treatment
- Skin sensitivity rises, so procedures and strong topicals are paused
- It is a substantial drug for a non-dangerous condition, and that trade-off is the conversation
Pregnancy: Isotretinoin is one of the most potent human teratogens in clinical use and is absolutely contraindicated in pregnancy. Prescription is conditional on the pregnancy-prevention requirements attached to it in every market that licenses the drug.
Why it sits where it does: It is the top of the extensive-disease route because it changes the underlying conditions rather than treating the surface, and because nothing about its risk profile allows it to sit any lower.
Procedure Narrowband UVB phototherapy
Hospital-based ultraviolet therapy
Generally compatible
Narrowband UVB phototherapy
Hospital-based ultraviolet therapy
A supervised course of controlled ultraviolet exposure, delivered in a clinic, used for severe or widespread disease where the extent makes topical treatment impractical.
How it works
Ultraviolet B in a narrow band around 311 nanometres suppresses cutaneous immune activity and reduces Malassezia colonisation. It is the same modality used for psoriasis and eczema, applied here to a different inflammatory target.
What the evidence says limited
In an open study of 18 people with severe disease treated three times weekly for up to eight weeks, six cleared completely and twelve improved markedly. The result is encouraging and the study is small and uncontrolled.
Typical course
Two or three hospital visits a week over six to eight weeks. The attendance burden is the reason it suits fewer people than the evidence alone would suggest.
Commonly discussed side effects
- Sunburn-type erythema if a dose is misjudged
- Dryness and itch
- Cumulative photoageing over repeated courses
- A small long-term skin cancer consideration across many lifetime treatments
Worth knowing
- Cumulative lifetime exposure is tracked, which constrains how often courses can be repeated
- Photosensitising medicines are reviewed before starting
- Home ultraviolet devices and tanning beds are not the same treatment and are not substitutes for it
Pregnancy: Narrowband UVB involves no systemic drug and is among the treatments most often continued during pregnancy for inflammatory skin disease. Folate levels can fall with phototherapy, which is worth flagging to antenatal care.
Why it sits where it does: It sits between the oral antifungals and the retinoid because it treats extensive disease without adding a systemic drug, which is a real advantage for anyone the tablets do not suit.
On the horizon
Pipeline information current as of 2026-09-01
Listed here only if a treatment is in phase 3 trials, has been submitted to a regulator, or has been approved recently enough that availability is still changing. Earlier-stage work is left out because the attrition rate makes it a poor guide to anything, however promising the press release.
This changes nothing about what to do now. Nothing in this section changes what is available or advisable today. It is here so that a reader knows what is moving, not so that anyone defers treatment waiting for it.
Recently arrived
Roflumilast 0.3% topical foam (2023). Approved in the United States in December 2023 for seborrheic dermatitis from the age of nine, and the first genuinely new mechanism licensed for this condition in roughly two decades. Its phase 3 trial in 457 people reported clear or almost clear skin in 79.5% at eight weeks against 58.0% on vehicle. The more interesting fact for anyone reading this outside the United States is that a European expert consensus published in 2026 declined to include it, on the stated basis that most of its panel voted against covering regimens not registered in the European Union.
In late-stage development
Roflumilast foam 0.3%, Chinese registration programme
Phase 3Hangzhou Zhongmei Huadong Pharmaceutical
A vehicle-controlled phase 3 trial of the same 0.3% roflumilast foam already approved in the United States, run to support registration in China.
Why it's notable: It is a geography study rather than a science one, and that is precisely why it is worth listing: for most of the world, access to this drug is a registration question rather than an evidence question.
Registered as not yet recruiting with a planned start in August 2026. Nothing about it changes availability in any market that has already approved or declined the drug.
This is a thin pipeline, and the thinness is the finding rather than an omission. A trawl of registered phase 3 and phase 4 trials in seborrheic dermatitis returns almost nothing current beyond regional registration work for a drug that already exists — the substantive trials on the list are ten and twenty years old. Attention followed roflumilast's approval and has not yet been followed by a wave of new candidates, so the realistic expectation for the next few years is wider access to what exists rather than a new mechanism.
Things people arrive already asking about
This condition attracts a large amount of adjacent advice, some of it reasonable and some of it not. Placement is what is useful here — neither dismissal nor enthusiasm, just where each thing actually sits against the evidence.
- Tea tree oil limited evidence
Genuine antifungal activity in laboratory conditions, and a small trial in dandruff reporting improvement. What is missing is evidence in facial disease specifically, and what is present is a notable rate of contact allergy — tea tree is a recognised sensitiser, and oxidised oil more so. On a face that is already inflamed, that risk is not trivial.
- Honey applied to the skin limited evidence
A small study reported improvement with diluted crude honey applied to affected facial skin, which is frequently cited and rarely qualified. It is one small uncontrolled study; the finding is interesting and not a basis for substituting it for an antifungal. The sticky reality of applying it also limits how many people continue.
- Dietary changes and sugar restriction limited evidence
Observational work has linked dietary patterns to seborrheic dermatitis severity, and the association is not strong enough to support a specific dietary prescription. What is better established is that alcohol is associated with the condition, and heavy drinking is a recognised risk factor — which is a genuine and unwelcome finding rather than a lifestyle suggestion.
- Picosecond Nd:YAG laser backed by smaller studies
A single-blind randomised trial in 63 people found adding one laser session to a topical calcineurin inhibitor improved erythema and scaling beyond the topical alone. One trial, one device, one centre — enough to be worth raising with a dermatologist, and not enough to sit on a ladder.
- Probiotics and microbiome products limited evidence
The mechanistic case is attractive, since the condition is a response to an organism that lives on the skin. The clinical evidence is early, mostly small, and not yet at the point where a specific product can be recommended for facial disease. This is an area genuinely worth watching rather than one to spend on now.
- Zinc supplements taken orally limited evidence
Zinc deficiency can produce an eruption that mimics stubborn seborrheic dermatitis, particularly in infants and in adults on parenteral nutrition, and correcting a genuine deficiency resolves it. That is a specific circumstance, not a general one — supplementing zinc in someone who is not deficient has no established effect on ordinary disease.
- Apple cider vinegar rinses limited evidence
Widely recommended online and unsupported by any trial in this condition. The acid does not reach a concentration that meaningfully affects Malassezia at dilutions safe for facial skin, and at concentrations that might, it burns. There are cheap effective options on the same shelf with actual monograph recognition.
Common questions
Why does it always come back after treatment that clearly worked?
Because clearing and controlling are two different treatments at two different frequencies, and only the first is usually described. Seborrheic dermatitis is a reaction to a yeast that lives permanently on facial skin; treatment suppresses the reaction without removing the resident. Stop, and the conditions that produced it are exactly as they were. The trial evidence puts a number on it — continuing a weekly antifungal after clearance cut six-month relapse from roughly 47% to 19%.
Is this the same thing as dandruff?
The same disease process in a different place, and the places behave differently enough to need separate handling. A scalp tolerates concentrations, contact times and vehicles that facial skin does not, and the face has two complications a scalp does not have: the eyelid margin, and the low ceiling on how long a corticosteroid can be used. The actives overlap almost completely; the schedules and the formats do not.
Is an antifungal shampoo safe to use on the face?
Directing an antifungal shampoo onto facial skin as a brief-contact wash is routine clinical advice, and it is the standard workaround in countries where the stronger cream is prescription-only. It is technically off-label, since the over-the-counter product is licensed for dandruff. Ketoconazole and zinc pyrithione are the two best tolerated that way; selenium sulfide stings enough on facial skin that most people stop.
How long can hydrocortisone be used on the face?
Days to a fortnight during an inflamed flare, alongside an antifungal, and then it stops. In the United Kingdom the over-the-counter pack carries an explicit instruction not to use it on the face without speaking to a pharmacist first, and a seven-day ceiling on unsupervised use. Continued for months it produces thinning, visible vessels and eruptions around the mouth and nostrils, all of which outlast the flare it was treating.
Why is a stronger antifungal cream available in a British pharmacy but not an American one?
Because the two countries built their over-the-counter categories differently rather than because either judged the drug differently. Ketoconazole is absent from the American monograph that governs this category and reached American shelves through a drug approval — but only at 1%, in shampoo. The 2% cream remains prescription-only there, while several European markets sell it as a pharmacy medicine. It is the largest practical difference on this page depending on where the reader lives.
Does washing the face more often help?
It reliably makes it worse, which is the most counterintuitive thing about the condition. Facial seborrheic dermatitis looks like something that should be washed away, and the flaking, the greasiness and the visible scale all invite more cleansing. Every increase in surfactant, heat, scrubbing or exfoliation raises inflammation on skin that is already dry underneath the grease. Soap substitution is a treatment step here, not a comfort measure.
Do the pale patches left behind become permanent?
They usually resolve, though on a much slower clock than the scaling does. Loss of pigment following seborrheic inflammation is common on richly pigmented skin and is often the feature that brings someone in, since it is more visible than the redness. Pigment typically returns over months once the inflammation is controlled — which is another argument for maintenance, because each new flare restarts the clock.
Sources and further reading
The staging, escalation points, and therapy descriptions on this page are anchored to published clinical guidelines rather than editorial judgment.
What this page is built on
- Practical recommendations for seborrheic dermatitis management: An expert consensus
- Seborrhoeic dermatitis: Clinical Knowledge Summary
The studies behind this pathway
The studies this page leans on, with the part of the argument each supports. Where a link is absent the citation is still complete enough to find, and no link is included that was not verified against the source record.
- Practical recommendations for seborrheic dermatitis management: An expert consensus The structural anchor for this page: first-line options for facial disease, the mild-to-moderate potency limit on facial corticosteroids, and escalation to systemic therapy in extensive disease.
- Topical antifungals for seborrhoeic dermatitis The evidence base for the antifungal tier, including ketoconazole's reduction in failure-to-clear against vehicle and its comparability to topical steroids with fewer adverse effects.
- Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp The corticosteroid and calcineurin-inhibitor side of the topical tier, and the basis for treating anti-inflammatory treatment as short-term rather than maintenance.
- Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial The central maintenance argument: weekly prophylaxis after clearance cut six-month relapse from around 47% to 19% among 312 people who had already responded.
- Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial The maintenance argument applied to facial skin specifically, and the dose-response within it: twice-weekly application held remission where once-weekly did not.
- Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial The roflumilast card and the recently-delivered pipeline entry: 79.5% versus 58.0% reaching clear or almost clear at eight weeks.
- Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study The ceiling stated at the top of the central-face ladder: benefit at covered sites, and no significant difference at exposed sites, which were mainly the face.
- Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis The ciclopirox card: 63% clearance against 34% on placebo at eight weeks in facial disease.
- Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis Why ciclopirox and the azoles share a rung rather than sitting in sequence.
- Lithium gluconate 8% vs. ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study The lithium card: complete response in 52.0% against 30.1% for ketoconazole among 269 people with moderate to severe disease.
- An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis The calcineurin-inhibitor card's efficacy claim: roughly 86% improvement in each arm, with no significant difference between them.
- Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults Why a calcineurin inhibitor displaces a corticosteroid in longer-term facial use rather than sitting above it in potency.
- Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study The point that a steroid and an antifungal clear at similar rates while relapse rates do not differ — which is why the antifungal carries the maintenance and the steroid does not.
- Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study The metronidazole card and its evidence-strength chip: comparable improvement to ketoconazole in a trial of 60 people.
- Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial The oral itraconazole card, including the pulsed schedule and its effect on relapse rather than clearance alone.
- Efficiency of terbinafine 1% cream in comparison with ketoconazole 2% cream and placebo in patients with facial seborrheic dermatitis That topical antifungals of different classes perform comparably on the face, which underpins treating them as alternatives within a rung.
- Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis The phototherapy rung on the extensive-disease route, and the honest note that its evidence is a small uncontrolled series.
- Seborrheic Dermatitis in Skin of Color: Clinical Considerations The deeper-skin-tones modifier: hypopigmented and petaloid presentations, and the tendency for severity to be underestimated where erythema is hard to see.
- Seborrheic dermatitis and risk of future Parkinson's disease The Parkinson disease association behind one of the red flags and one of the staging modifiers. Presented as a meeting abstract, which is why no linked record is offered here.
Everything on this page traces back to the sources below. The consensus document is written for clinicians and is dense; the patient-facing pages are the better starting point for anyone wanting a second description of the condition in plainer terms.
Guidance and consensus
There is no formal national guideline for seborrheic dermatitis in the way there is for acne or eczema — the 2026 European consensus says so explicitly, describing itself as practical guidance offered where formal guidelines are lacking. These two documents are what the structure of this page follows.
- Practical recommendations for seborrheic dermatitis management: An expert consensus European Academy of Dermatology and Venereology A modified Delphi process among 33 dermatologists, reaching consensus on 44 statements covering acute treatment and long-term maintenance.
- Seborrhoeic dermatitis — Clinical Knowledge Summary National Institute for Health and Care Excellence The primary-care management summary used across the UK, organised by site. Access is restricted to the UK and its dependencies.
Patient-facing descriptions
Useful for a second account of what the condition is and how it behaves, written for readers rather than for prescribers.
- Seborrheic dermatitis: self-care American Academy of Dermatology The American dermatology body's own advice on living with it day to day, which is the half of this condition that lasts longest.
- Seborrheic dermatitis: causes and treatment DermNet More clinical detail than most patient resources, with a good set of clinical images across skin tones.
Regulatory and label sources
Where the claims about what may be sold, and at what strength, come from.
- OTC Monograph M032 — dandruff, seborrheic dermatitis and psoriasis drug products US Food and Drug Administration The document behind the concentration bands quoted on this page, including the separate seborrheic dermatitis floor for zinc pyrithione.
- Roflumilast topical foam 0.3% — approval package US Food and Drug Administration The December 2023 approval for seborrheic dermatitis in patients aged nine and older.
Take the charts with you
Print exactly the piece you need. Each chart is one landscape page — no prose, no controls, sized to pin up or hand to someone — and the full document is the whole pathway as it reads on screen. Every printout carries the date, the source, and a line making clear it is not a diagnosis.
Printing happens in your browser. Your answers stay private — saved on this device, and to your free account when you're signed in.